{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["b9014dc0-e00a-4d03-9e69-61f96b4ce868", "Q3", 7257, "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 211669, "AIPHARMA GLOBAL HOLDINGS LIMITED", 2021, "third_quarter", "2021-10-18T17:28:08.097000-04:00", 80000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/b9014dc0-e00a-4d03-9e69-61f96b4ce868/\", \"filing_uuid\": \"b9014dc0-e00a-4d03-9e69-61f96b4ce868\", \"filing_type\": \"Q3\", \"filing_type_display\": \"3rd Quarter - Report\", \"filing_year\": 2021, \"filing_period\": \"third_quarter\", \"filing_period_display\": \"3rd Quarter (July 1 - Sep 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/b9014dc0-e00a-4d03-9e69-61f96b4ce868/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"80000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Marc S. Lampkin, Attorney at Law\", \"dt_posted\": \"2021-10-18T17:28:08.097000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": \"United States of America\", \"registrant_address_1\": \"1155 F ST. NW\", \"registrant_address_2\": \"1200\", \"registrant_different_address\": false, \"registrant_city\": \"WASHINGTON\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20004\", \"registrant\": {\"id\": 7257, \"url\": \"https://lda.senate.gov/api/v1/registrants/7257/\", \"house_registrant_id\": 31842, \"name\": \"BROWNSTEIN HYATT FARBER SCHRECK, LLP\", \"description\": \"Law firm\", \"address_1\": \"600 Massachusetts Ave, NW\", \"address_2\": \"Suite 400\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20001\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"QUINN MCKAY\", \"contact_telephone\": \"+1 202-872-5292\", \"dt_updated\": \"2026-01-30T13:54:08.460364-05:00\"}, \"client\": {\"id\": 211669, \"url\": \"https://lda.senate.gov/api/v1/clients/211669/\", \"client_id\": 1010965, \"name\": \"AIPHARMA GLOBAL HOLDINGS LIMITED\", \"general_description\": \"Pharmaceuticals\", \"client_government_entity\": false, \"client_self_select\": null, \"state\": null, \"state_display\": null, \"country\": \"IE\", \"country_display\": \"Ireland\", \"ppb_state\": null, \"ppb_state_display\": null, \"ppb_country\": \"IE\", \"ppb_country_display\": \"Ireland\", \"effective_date\": \"2021-07-16\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"Issues related to the pharmaceutical supply chain\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 107295, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MARK\", \"nickname\": null, \"middle_name\": \"L.\", \"last_name\": \"PRYOR\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 103206, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"ADAM\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"STEINMETZ\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 33975, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"DAVID\", \"nickname\": null, \"middle_name\": \"PHILLIP\", \"last_name\": \"COHEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 66261, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"ANDREW\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"LITTMAN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 143842, \"prefix\": \"ms\", \"prefix_display\": \"MS.\", \"first_name\": \"LAURA\", \"nickname\": null, \"middle_name\": \"JOHNSON\", \"last_name\": \"BOLLIER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 139, \"name\": \"Natl Institutes of Health (NIH)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 12, \"name\": \"White House Office\"}]}, {\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"Issues related to the pharmaceutical supply chain\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 70425, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"EMILY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"FELDER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 139, \"name\": \"Natl Institutes of Health (NIH)\"}, {\"id\": 1, \"name\": \"SENATE\"}, {\"id\": 12, \"name\": \"White House Office\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["b9014dc0-e00a-4d03-9e69-61f96b4ce868"], "units": {}, "query_ms": 2.9922989197075367, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}